Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE

Abstract

Background Erenumab is a fully human monoclonal antibody and a highly potent, first-in-class calcitonin gene-related peptide receptor inhibitor approved for migraine prevention in adults. Randomised, placebo-controlled trials show that erenumab treatment results in clinically meaningful responses, including significant reductions in monthly migraine days. Real-world evidence of the effectiveness of erenumab in patients with migraine is accruing, but gaps remain, and findings may vary according to region. We evaluated the usage patterns and effectiveness of erenumab in real-world settings in patients with migraine in the United Arab Emirates (UAE). Methods This retrospective, observational real-world study enrolled patients ≥ 18 years with migraine who were prescribed erenumab in the UAE. Data were collected at baseline and Months 1, 3 and 6. The primary study objective was to characterise usage patterns of erenumab in patients with chronic migraine (CM) or episodic migraine (EM) in real-world settings in the UAE. Results Of the 166 patients, 124 (74.7%) were females. The mean (standard deviation) age at migraine onset was 29 (7.93) years. Seventy-one patients (42.8%) had CM and 95 (57.2%) had EM. In the overall population, the mean monthly headache/migraine days (MHD) at baseline was 15.7 (8.45) and mean change from baseline was − 8.2 (8.83) at Month 1, − 11.0 (9.15) at Month 3 and − 11.3 (8.90) at Month 6. The mean change from baseline in monthly acute migraine-specific medication days (MSMD) was − 9.0 (8.07) at Month 1, − 9.7 (8.73) at Month 3 and − 10.7 (8.95) at Month 6. At all time points, most patients achieved at least 50% reduction in MHD (80%–91%) and MSMD (84%–94%). Similar reductions in MHD and MSMD and clinical benefit in CM or EM were seen with erenumab monotherapy or erenumab add-on therapy, with or without dose escalation and for treatment naïve or ≥ 1 previous preventive treatment failures, with additional clinical benefit in the erenumab add-on therapy and dose escalation to 140 mg subgroups. Conclusion In this real-world study on erenumab use in the UAE, patients prescribed erenumab achieved clinically meaningful reductions in MHD and MSMD at all assessed time points. Erenumab was well tolerated with no new safety events.

Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry

“…Nonetheless, although our findings are overall in agreement with the results reported in the FRIEND study, a direct comparison cannot be done because of significant differences in the number of patients studied (67 vs. 204 in our study) and different medical histories and comorbidities. Moreover, we report similar findings to those recently published for erenumab [19][20][21] and galcanezumab [22,23] in real-world studies in both the EM and CM settings, although again methodological differences exist between studies, including the evaluation of changes in monthly migraine days (MMD) rather than MHD and the definition of the cut-off for treatment response at the level of 30% rather than 50% reduction in MHD. TA B L E 3 Changes in efficacy, disability, and quality of life outcomes at baseline (T0-trimester before initiation of therapy) and after fremanezumab treatment in patients with chronic migraine (n = 107).…”

Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study

“…To our knowledge, this study represents the first real-world evidence study of intravenous migraine treatment and the first study examining the efficacy and tolerability of intravenous migraine medication among chronic and episodic migraine patients in the UAE. Similar to our study, other real-world data on other mAbs have validated our understanding of the effectiveness of these therapies [ 11 , 12 ]. Furthermore, the current study included diverse pools of patients in terms of their prior preventive therapies’ exposure in their treatment; the inclusion of naïve patients, as well as those with PPTF for migraine headache, allows for possible insights into how eptinezumab’s efficacy may be impacted by prior medication history.…”

Effectiveness, and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A retrospective study

“…To our knowledge, this study represents the rst real-world evidence study of intravenous migraine treatment and the rst study examining the e cacy and tolerability of intravenous migraine medication among chronic and episodic migraine patients in the UAE. Similar to our study, other real-world data on other mAbs have validated our understanding of the effectiveness of these therapies [12,13]. Furthermore, the current study included diverse pools of patients in terms of their prior preventive therapies' exposure in their treatment; the inclusion of naïve patients, as well as those with PPTF for migraine headache allows for possible insights into how Eptinezumab-jjmr's e cacy may be impacted by prior medication history.…”